New developments in clinical trials and drug approvals have become commonplace. And buyouts of biotech stocks at high premiums are increasing. Here is how to get your share of the outsized gains that are being generated. Let’s explore the issue with the help of two charts. Please click here for an annotated
This post was just published on ZYX Buy Change Alert. A quick denial of a potential deal is not typical, as has happened in the case of FLXN. One hypothetical explanation is that the deal is potentially in the works but a quick run-up in the stock makes the deal difficult. Hypothetically,
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence
Mom and pop investors love to read about the stocks that billionaires have been buying or selling. The media is happy to oblige. After all, what is good for the likes of Warren Buffet and Carl Icahn has to be good for mom and pop, right? Wrong! Let me explain why it